Trial reportAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2013
Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients.
Trial report in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03519464 (A Phase 2, Open-Label Study to Assess the Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in Patients With Idiopathic CD4 T Cell Lymphocytopenia), which is not on this map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2, Open-Label Study to Assess the Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in Patients With Idiopathic CD4 T Cell Lymphocytopenia
Who cites it
44 citing papers in PubMed, 134 citations in OpenAlex.
- Quadrivalent HPV (4vHPV) vaccine immunogenicity and safety in women using immunosuppressive drugs due to solid organ transplant.Frontiers in cellular and infection microbiology · 2024Trial
- Article
- Effectiveness, immunogenicity and safety of human papillomavirus vaccination in non-HIV immunocompromised individuals: a systematic review.EClinicalMedicine · 2026Article
- The Role of Vaccination in Adult Solid Organ Transplantation: Updated Reviews with Recent Guidelines.Microorganisms · 2026Review
- Article
- Updated Review for Guidelines for Cervical Cancer Screening in Immunosuppressed Women Without HIV Infection.Journal of lower genital tract disease · 2025Review
- Sexually transmitted human papillomavirus and related sequelae.Clinical microbiology reviews · 2025Review
- Article
- The Long-Term Immunogenicity of mRNABNT162b Third Vaccine Dose in Solid Organ Transplant Recipients.Vaccines · 2024Article
- Immunogenicity and safety of the fourth dose of quadrivalent human papillomavirus (HPV) vaccine in immunosuppressed women who did not seroconvert after three doses.Frontiers in cellular and infection microbiology · 2024Article
- Understanding human papillomavirus vaccine response and efficacy in people living with HIV: A systematic mixed studies review and meta-analysis.PLOS global public health · 2024Article
- ANAL CANCER IN A RENAL TRANSPLANT RECIPIENT: A CASE REPORT AND LITERATURE REVIEW.Acta clinica Croatica · 2023Review
- Vaccination Recommendations in Solid Organ Transplant Adult Candidates and Recipients.Vaccines · 2023Review
- Women's health issues in solid organ transplantation: Breast and gynecologic cancers in the post-transplant population.World journal of transplantation · 2023Review
- Approach to vaccinating the pediatric solid organ transplant candidate and recipient.Frontiers in pediatrics · 2023Article
- Human papillomavirus vaccination uptake among childhood cancer survivors in Western New York.Pediatric blood & cancer · 2022Article
- Optimizing Immunization Strategies in Adult Patients With Chronic Liver Disease and Liver Transplant Recipients.Gastroenterology & hepatology · 2022Article
- Review
- Risk of human papillomavirus infection and cervical intraepithelial lesions in Chinese renal transplant recipients.Frontiers in oncology · 2022Article
- Human papillomavirus infection-related cancer risk for kidney transplant recipients during adult life can be reduced by vaccination during childhood and adolescence.Frontiers in pediatrics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Solid organ transplant recipients are at risk of morbidity from human papillomavirus (HPV)-related diseases. Quadrivalent HPV vaccine is recommended for posttransplant patients but there are no data on vaccine immunogenicity. We determined the immunogenicity of HPV vaccine in a cohort of young adult transplant patients. Patients were immunized with three doses of quadrivalent HPV vaccine containing viral types 6, 11, 16 and 18. Immunogenicity was determined by type-specific viral-like protein ELISA. Four weeks after the last dose of vaccine, a vaccine response was seen in 63.2%, 68.4%, 63.2% and 52.6% for HPV 6, 11, 16 and 18, respectively. Factors that led to reduced immunogenicity were vaccination early after transplant (p = 0.019), having a lung transplant (p = 0.007) and having higher tacrolimus levels (p = 0.048). At 12 months, there were significant declines in antibody titer for all HPV types although the number of patients who remained seropositive did not significantly differ. The vaccine was safe and well tolerated. We show suboptimal immunogenicity of HPV vaccine in transplant patients. This is important for counseling patients who choose to receive this vaccine. Further studies are needed to determine an optimal HPV vaccine type and schedule for this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.